

*Paris and Toulouse, France – March 6<sup>th</sup>, 2015*

## **IMPLEMENTATION OF A PROGRAMMED TRADING MANDATE**

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that Edmond de Rothschild Investment Partners (EdRIP), a Supervisory Board member, has conferred a programmed trading mandate to an independent investment bank, Oddo Corporate Finance, for EdRIP's funds, shareholders in Genticel.

This programmed trading mandate concerns the divestment of a maximum of 865,427 shares, representing approximately 5.6% of Genticel's shares outstanding as of March 6<sup>th</sup>, 2015, over a 12-month maximum period beginning on June 4<sup>th</sup>, 2015. This partial divestment is necessary because certain of EdRIP's funds will reach maturity during the mandate's period. The programmed trading mandate will be implemented in accordance with the terms and conditions, effective as of November 3<sup>rd</sup> 2010, stipulated in Recommendation n°2010-07 of the *Autorité des marchés financiers* (France's stock market regulators).

### **Financial calendar 2015**

<b>28 April 2015</b>	Update on 2015 1 <sup>st</sup> Quarter Business & Cash Position
<b>11 June 2015</b>	Annual Shareholders Meeting
<b>28 July 2015</b>	Update on 2015 2 <sup>nd</sup> Quarter Business & Cash Position
<b>21 September 2015</b>	2015 Half-Year Results
<b>28 October 2015</b>	Update on 2015 3 <sup>rd</sup> Quarter Business & Cash Position

### **Upcoming Genticel meetings with investors**

<b>19 March 2015</b>	KBC Securities Healthcare Conference - Brussels, Belgium
<b>21 March 2015</b>	Bolero's Biotech Retail Event, associated with Flandersbio - Leuven, Belgium
<b>25 April 2015</b>	VFB Investor Happening - Brussels, Belgium
<b>27 &amp; 28 April 2015</b>	Small & Midcap Event - Paris



**About Genticel**

*Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.*

*Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.*

*Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.*

*Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.*

*For more information, please visit Genticel's website, [www.genticel.com](http://www.genticel.com)*



**GENTICEL CONTACT**

Benedikt Timmerman  
Chief Executive Officer  
[investors@genticel.com](mailto:investors@genticel.com)

**USA INVESTOR CONTACT**

Brian Stollar  
Tel.: +1 (212) 915 2577  
[bstollar@lifesciadvisors.com](mailto:bstollar@lifesciadvisors.com)

**INVESTOR CONTACT**

Corinne Puissant  
Tel.: +33 (0)1 53 67 36 77  
[cpuissant@actus.fr](mailto:cpuissant@actus.fr)

**PRESS CONTACT**

Alexandra Prisa  
Tel.: +33 (0)1 53 67 36 90  
[aprisa@actus.fr](mailto:aprisa@actus.fr)